CD47 and neoplasm: Importantly, anti‐CD47, which blocks the CD47‐SIRPα inhibitory signaling axis on RBCs, selectively impaired RBC‐exosome uptake (P < 0.05) without affecting tumor‐exosome attachment and internalization.